Navigation Links
Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
Date:2/5/2010

BOSTON, Feb 5 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce the Company has signed an agreement with Expert Resource (ER) to provide consulting services in support of the Company's ISO 13485 quality management system (QMS) initiative. Expert Resource will provide comprehensive consulting, training and document preparation for Solos Endoscopy to create a quality management system that meets the requirements of the ISO 13485 standard. Compliance with ISO 13485 is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union.

Expert Resource is an international consulting and training firm specializing in business improvement initiatives. ER helps medical device and medical laboratory companies implement ISO 13485, ISO 15189, ISO 14971, or GMP quality systems, obtain the CE Mark, submit FDA 510(k) applications, assist with clinical trials, and more. For more information on Expert Resource, visit www.expertresource.net.

"It has been our goal to expand our markets into Canada and the European Union," stated Bob Segersten, President of Solos Endoscopy, Inc. "Expanding into the EU and Canada presents enormous sales opportunities for Solos Endoscopy. We are pleased to be working with Expert Resource to provide the specialized assistance we need in developing our management and manufacturing systems in order to ultimately obtain the CE Mark."

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.

RELATED LINKS
http://www.solosendoscopy.com

'/>"/>

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in February Issue of General Surgery News
2. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
3. Solos Endoscopy, Inc. Outlines Marketing Strategy for 2010 Campaign
4. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
5. Solos Endoscopy, Inc. Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
6. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
7. Solos Endoscopy, Inc. Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
8. Solos Endoscopy, Inc. Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Product Line
9. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
10. Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line
11. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
Breaking Medicine Technology:
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: A Story ... parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of Love” is ... Island, New York. , Published by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s ...
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, 2017 — ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , According ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, ... new charity drive to generate community support for efforts to educate the local population ... treatments for all types of cancer. , Each day in America, roughly 4,600 ...
Breaking Medicine News(10 mins):